2型糖尿病和酸盐:揭开一个古老的分子
Sonia Fernández-Veledo1,2,3, Anna Marsal-Beltran4,5,6, Joan Vendrell4,5,6
1Hospital Universitari Joan XXIII de Tarragona, Institut d'Investigació Sanitària Pere Virgili (IISPV)-CERCA, Tarragona, Spain. sonia.fernandez@urv.cat.
Diabetologia
|January 5, 2024
概括
苏酸盐是一种参与能量生产的代谢物,也起到细胞外信使的作用,调节代谢和免疫反应. 向酸盐-酸盐受体1 (SUCNR1) 轴为治疗糖尿病及其并发症提供了新的治疗策略.
科学领域:
- 代谢生物化学 代谢生物化学
- 细胞信号传递 细胞信号传递
- 内分泌学 在内分泌学.
背景情况:
- 传统上与细胞内能量生产相关的代谢物可以作为细胞外信号分子起作用.
- 来自营养,肠道微生物群或宿主代谢的信号代谢物是代谢和免疫过程的关键调节者.
- 酸盐是具有双重作用的关键代谢物,参与克雷布斯循环和线粒体呼吸,同时也作为细胞外信号发射器.
研究的目的:
- 综述酸盐的多方面的作用,特别是其作为信号分子的功能.
- 在糖尿病的背景下探索酸盐-酸盐受体1 (SUCNR1) 轴的参与.
- 讨论作为潜在的生物标记物的苏酸盐和针对糖尿病管理的SUCNR1轴的治疗潜力.
主要方法:
- 文献综述侧重于简要的双重作用.
- 在新陈代谢调节中分析酸盐-SUCNR1信号通路.
- 探索针对苏酸盐-SUCNR1轴的治疗策略.
主要成果:
- 突出了酸盐作为能量代谢物和细胞外信号的双重功能.
- 苏酸盐-SUCNR1轴与糖尿病的病理生理学有关.
- 苏酸显示出作为糖尿病生物标志物的潜力.
结论:
- 准糖酸盐-SUCNR1轴为糖尿病管理提供了一个有前途的治疗途径.
- 策略包括对SUCNR1的药理调节和通过给药或微生物群调节来管理糖酸盐度.
- 了解酸盐复杂的作用,可以了解代谢疾病和新的治疗方法.
相关概念视频
Oral Hypoglycemic Agents: Sulfonylureas
210
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
210
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K
Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206
Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
Depolarizing Blockers: Pharmocokinetics
327
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
327


